Should the pharmaceutical industry consider using high-order autoregressive models when modelling panel data?
制药行业面板数据建模是否应考虑高阶自回归结构?AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要直接讨论患者纵向面板数据中重复测量模型的相关结构设定。
制药行业面板数据建模是否应考虑高阶自回归结构?AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Longitudinal data, often in the form of panel data, are commonly encountered in the pharmaceutical industry. However it is not always possible to fit an unstructured covariance matrix when using the Mixed Model for Repeated Measures (MMRM). Here we argue that high-order autoregressive models provide a useful framework when more general correlation structures, such as the unstructured and/or Toeplitz, are unfeasible. The autoregressive model of order one is often suggested but, in our experience, higher orders are seldom considered. We present the case for using autoregressive models, with potentially high orders, as a flexible framework to model correlations in panel data, when more general structures are hard to identify.